Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients
Launched by ASTRAZENECA · Oct 30, 2008
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Life expectancy of at least 12 weeks
- • Histologically confirmed metastatic cancer, not amenable to surgery or radiation therapy with curative intent
- • Patients with measurable or non measurable disease according to RECIST
- Exclusion Criteria:
- • Less than 28 days from active therapy (ie any treatment used to treat the disease) or high dose radiotherapy
- • Brain Metastases or spinal cord compression unless irradiated at least 4 weeks before entry and stable without steroid treatment for \>1 week
- • Persistent CTCAE Grade 2 or greater toxicities (excluding alopecia) caused by prior therapy
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Barcelona, , Spain
Patients applied
Trial Officials
Jane Robertson, BSc, MBCHB, MD
Study Director
AstraZeneca
Judy E Garber
Principal Investigator
Dana-Farber Cancer Institute
J Ballmana Gelpi
Principal Investigator
Vall d'Hebron
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials